Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy (Q38428834)

3 September 2017

Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy (English)

1 reference

3 September 2017

Su-Mi Kim

1

1 reference

3 September 2017

Sang-Ho Lee

2

1 reference

3 September 2017

Yang-Gyun Kim

3

1 reference

3 September 2017

Se-Yun Kim

4

1 reference

3 September 2017

Jung-Woo Seo

5

1 reference

3 September 2017

Young-Wook Choi

6

1 reference

3 September 2017

Dong-Jin Kim

7

1 reference

3 September 2017

Kyung-Hwan Jeong

8

1 reference

3 September 2017

Tae-Won Lee

9

1 reference

3 September 2017

Chun-Gyoo Ihm

10

1 reference

3 September 2017

Kyu-Yeoun Won

11

1 reference

3 September 2017

Ju-Young Moon

12

1 reference

3 September 2017

28 January 2015

1 reference

American Journal of Physiology - Renal Physiology

3 September 2017

1 reference

3 September 2017

308

1 reference

3 September 2017

F993-F1003

1 reference

3 September 2017

9

1 reference

Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus.

3 September 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

A study of the natural history of diabetic kidney disease (DKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

NF-κB, inflammation, and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

A tissue-specific role for Nlrp3 in tubular epithelial repair after renal ischemia/reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Nlrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Sterile inflammation: sensing and reacting to damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Inflammation and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Allopurinol as a cardiovascular drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Aberrant recruitment and activation of T cells in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Interaction between uric acid and HMGB1 translocation and release from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

The NLRP3 inflammasome promotes renal inflammation and contributes to CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00637.2014

10.1152/AJPRENAL.00637.2014

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference